Karyopharm Files Chapter 11 to Pursue Ayrmid Merger; Equity Expected to Have No Value
Karyopharm entered a Restructuring Support Agreement with its existing lenders, noteholders and other key stakeholders that provides for a merger with Ayrmid Ltd. To carry it out, the company filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas. The company expects its existing equity securities to have no value, and holders of common stock and Convertible Preferred Stock would receive no payment under the plan.
Key points
- Voluntary Chapter 11 petitions filed in the U.S. Bankruptcy Court for the Southern District of Texas
- Holders of common stock and Convertible Preferred Stock would receive no payment or distribution under the Prepackaged Plan
- Up to $55 million in debtor-in-possession financing committed by existing secured lenders, subject to Court approval
- Transaction expected to close in the first quarter of 2027; court-supervised bidding procedures allow competing bids
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.